Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

24.68 +0.14 (+0.57%)
Streaming Delayed Price Updated: 11:17 AM EDT, Apr 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Are Investors Being Too Paranoid About Pfizer Stock?
Via The Motley Fool
Zoetis (NYSE:ZTS) Posts Q4 Sales In Line With Estimates But Stock Drops
Animal health company Zoetis (NYSE:ZTS) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 4.7% year on year to $2.32 billion. On the other hand, the company’s full-year revenue... 
Via StockStory
3 Brand-Name, Ultra-High-Yield Dividend Stocks Patient Investors Can Confidently Buy With $300 Right Now
A trio of high-octane income stocks -- sporting an average yield of 6.65% -- can fatten investors' pocketbooks in 2025 (and well beyond). 
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
U.S. FDA Approves Pfizer’s ADCETRIS® Combination Regimen for the treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
From Pfizer Inc.
Via Business Wire
Pfizer's Options Frenzy: What You Need to Know
Via Benzinga
Earnings To Watch: Zoetis (ZTS) Reports Q4 Results Tomorrow
Animal health company Zoetis (NYSE:ZTS) will be reporting results tomorrow before market open. Here’s what to look for. 
Via StockStory
Organon (OGN) Q4 Earnings Report Preview: What To Look For
Pharmaceutical company Organon (NYSE:OGN) will be reporting earnings tomorrow before market hours. Here’s what investors should know. 
Via StockStory
Pfizer/Astellas Tout Encouraging Data From Keytruda Combo Regime In Urothelial Cancer Showing 49% Reduction In Death Risk Vs. Chemo
Pfizer and Astellas' Padcev-Keytruda combo showed durable survival benefits in urothelial cancer, with a higher response rate and no new safety concerns. 
Via Benzinga
Pfizer and Astellas’ PADCEV® (enfortumab vedotin-ejfv) plus KEYTRUDA® (pembrolizumab) Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer (la/mUC)
From Pfizer Inc.
Via Business Wire
Is Now a Good Time to Buy the Dip on Pfizer?
Via The Motley Fool
Unpacking the Latest Options Trading Trends in Pfizer
Via Benzinga
Explore the S&P500 index on Monday and find out which stocks are the most active in today's session.
Let's have a look at what is happening on the US markets on Monday. Below you can find the most active S&P500 stocks in today's session. 
Via Chartmill
Super Bowl Commercials 2025: Complete List of Super Bowl LIX Ads And Companies Behind Them
The list of Super Bowl LIX commercials and the companies behind the Super Bowl ads. 
Via Benzinga
These Stocks Missed on Earnings, But Will Rebound Next Quarter
Here are three stocks from companies that missed on earnings but have strong support from analysts that makes each stock a solid Buy for the next year 
Via MarketBeat
Royalty Pharma Earnings: What To Look For From RPRX
Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) will be reporting earnings tomorrow morning. Here’s what to look for. 
Via StockStory
Better High-Yield Dividend Stock: Pfizer vs. Merck
Via The Motley Fool
3 No-Brainer Healthcare Stocks to Buy With $200 Right Now
Via The Motley Fool
3 Dividend Stocks to Double Up on Right Now
Via The Motley Fool
10 Undervalued Hidden Gem Dividend Stocks For Savvy Investors
Income investors should focus on higher-yielding securities, if they want additional income from their stock portfolios. 
Via Talk Markets
Topics Stocks / Equities
Most active S&P500 stocks in Thursday's session
Stay informed about the most active S&P500 stocks in today's session as we take a closer look at what's happening on the US markets on Thursday. Discover the stocks that are generating the highest... 
Via Chartmill
Arcutis Soared In 2024, Blazing Trails In Dermatology. Why Its CEO Eyes Bigger Gains.
The company won three FDA approvals over the past two years. Now, it's angling for two new approvals in 2025. 
Via Investor's Business Daily
Exposures Product Safety
What Drives Billionaire Masayoshi Son?
The man behind SoftBank has now teamed up with OpenAI to invest up to $500 billion in American AI infrastructure over the next four years. 
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Earnings To Watch: Bristol-Myers Squibb (BMY) Reports Q4 Results Tomorrow
Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) will be reporting results tomorrow before the bell. Here’s what you need to know. 
Via StockStory
What To Expect From Eli Lilly’s (LLY) Q4 Earnings
Global pharmaceutical company Eli Lilly (NYSE:LLY) will be reporting results tomorrow morning. Here’s what to expect. 
Via StockStory
Looking for the most active stocks in the S&P500 index on Tuesday?
Looking for the most active S&P500 stocks in today's session? Join us as we dive into the US markets on Tuesday and discover the stocks that are dominating the trading activity and setting the pace for... 
Via Chartmill
Pfizer (PFE) Q4 2024 Earnings Call Transcript
PFE earnings call for the period ending December 31, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Pfizer Shares Are Falling Today: What's Going On?
Pfizer Inc. (NYSE: PFE) shares are trading lower Tuesday after the Senate Finance Committee voted to advance Robert F. Kennedy Jr.'s nomination for Secretary of Health and Human Services. 
Via Benzinga
US Stocks Rise Despite China's Trade Fears, Palantir Defies Gravity, Gold Rallies Further: What's Driving Markets Tuesday?
U.S. stocks advanced midday Tuesday, demonstrating resilience despite escalating geopolitical tensions and trade uncertainties between the world’s two largest economies. 
Via Benzinga
Pfizer's Retail Traders Cheer Better-Than-Expected Q4 Even As Stock Dips: ‘Another Beat And Still Crazy Cheap'
Under its restructuring program, Pfizer said it remains on track to deliver $4.5 billion in cost savings by the end of 2025. 
Via Stocktwits
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS